8-K: Revelation Biosciences Reports Q3 2025 Results, Cash Extends to Q3 2026

Revelation Biosciences announced its financial results for the three and nine months ended September 30, 2025, highlighting positive clinical study results and an extended cash runway through Q3 2026.

Summary

• Cash and cash equivalents increased to $12.7 million as of September 30, 2025, compared to $6.5 million as of December 31, 2024.
• The company received gross proceeds of $9.6 million from a warrant inducement in September 2025.
• Net cash used for operating activities for the nine months ended September 30, 2025, was $6.3 million, a significant reduction from $14.6 million for the same period in 2024.
• Net loss for the three months ended September 30, 2025, was $1.9 million, or $(1.77) basic and diluted net loss per share, compared to $2.2 million, or $(40.15) per share, for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $6.4 million, or $(9.76) basic and diluted net loss per share, compared to $13.3 million, or $(354.05) per share, for the same period in 2024.
• Revelation Biosciences announced groundbreaking top-line results from its PRIME Clinical Study.
• Current cash and cash equivalents are projected to be sufficient to fund operations through the third quarter of 2026.

Sentiment

Score: 8

Explanation: The company reported significantly improved financial metrics, including reduced net loss and operating cash burn, and a substantial increase in cash reserves due to successful financing activities. Positive clinical trial results for its lead candidate, Gemini, and an extended cash runway through Q3 2026 indicate strong operational progress and a more stable financial position, despite continued net losses typical for a clinical-stage company.

Positives

• Cash and cash equivalents significantly increased to $12.7 million as of September 30, 2025, from $6.5 million as of December 31, 2024.
• Successfully raised $9.6 million in gross proceeds from a warrant inducement in September 2025, alongside net cash proceeds from a May 2025 public offering.
• Net cash used for operating activities for the nine months ended September 30, 2025, substantially decreased to $6.3 million from $14.6 million for the same period in 2024.
• Net loss for the three months ended September 30, 2025, decreased to $1.9 million from $2.2 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, decreased to $6.4 million from $13.3 million in the prior year period.
• Announced groundbreaking top-line results from the PRIME Clinical Study.
• Previously announced positive Phase 1b clinical data for Gemini in Chronic Kidney Disease (CKD) patients.
• Cash runway extended, providing sufficient funds to operate through the third quarter of 2026.

Negatives

• The company continues to incur net losses, reporting $1.9 million for Q3 2025 and $6.4 million for the nine months ended September 30, 2025.
• Total operating expenses increased slightly for both the three-month period ($1,943,011 in 2025 vs. $1,796,686 in 2024) and the nine-month period ($6,499,226 in 2025 vs. $6,221,221 in 2024) compared to the prior year.

Risks

• The ability of Revelation Biosciences to meet its financial and strategic goals may be adversely affected by competition.
• Challenges exist in the company's ability to grow and manage growth profitably and to retain its key employees.
• Revelation Biosciences may be adversely affected by other economic, business, and/or competitive factors.
• Risks are associated with the successful development of Revelation Biosciences' product candidates.
• The ability to successfully complete planned clinical studies of its product candidates is not guaranteed.
• There is a risk that clinical studies may not be fully enrolled or that enrollment will take longer than expected.
• Risks relate to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from clinical studies.
• Changes in applicable laws or regulations could impact the company's operations and product development.
• Uncertainty exists regarding the timing, costs, conduct, and outcome of other clinical studies.
• The anticipated treatment of future clinical data by regulatory authorities (FDA, EMA) is uncertain, including whether such data will be sufficient for approval.
• The success of future development activities for its product candidates is not assured.
• There are risks concerning the potential indications for which product candidates may be developed.
• The ability of Revelation Biosciences to maintain the listing of its securities on NASDAQ is a risk.
• The expected duration over which Revelation Biosciences' balances will fund its operations is an estimate and subject to change.

Future Outlook

Revelation Biosciences believes its current cash and cash equivalents are sufficient to fund operations through the third quarter of 2026. The company looks forward to meeting with the FDA later this year to gain agreement on the clinical development path to registration of Gemini, aiming to enhance shareholder value. Gemini is being evaluated for multiple indications, with acute kidney injury (AKI) being the primary focus due to the large market and potential for the shortest pathway to marketing approval.

Management Comments

• "The outstanding PRIME data and subsequent financing validate Gemini's potential and places the company on solid footing to advance the next phase of development." James Rolke, Chief Executive Officer.
• "We look forward to meeting with the FDA later this year to gain agreement on the clinical development path to registration of Gemini, in turn enhancing shareholder value." James Rolke, Chief Executive Officer.

Industry Context

Revelation Biosciences operates in the highly competitive clinical-stage life sciences sector, focusing on rebalancing inflammation. Its lead candidate, Gemini, targets acute and chronic inflammatory conditions, with a primary focus on acute kidney injury (AKI), a market currently lacking approved therapies. The positive clinical data for Gemini and extended cash runway position the company to advance its development programs, aligning with the industry's emphasis on addressing unmet medical needs through innovative therapies.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for enhanced shareholder value through advancing Gemini's development and regulatory pathway. The successful warrant inducement and public offering indicate continued investor interest and support. Reduced net loss and extended cash runway provide financial stability.
• Employees: Continued operations and advancement of clinical programs suggest job stability and potential for growth.
• Patients/Healthcare Providers: Potential for new therapies for acute kidney injury and other inflammatory conditions if Gemini successfully progresses through clinical development and gains approval.

Next Steps

• Meet with the FDA later this year (2025) to gain agreement on the clinical development path to registration of Gemini.
• Advance the next phase of development for Gemini.
• Continue evaluating Gemini for the treatment of acute kidney injury (Gemini-AKI), chronic kidney disease (GEMINI-CKD program), post-burn infection and hyper-inflammatory response (Gemini-PBI), and post-surgical infection (GEMINI-PSI program).

Key Dates

Recommendation

While Revelation Biosciences has demonstrated significant progress with positive clinical data for Gemini, a substantial reduction in cash burn, and an extended cash runway, it remains a clinical-stage company with no approved products and continues to incur net losses. The successful capital raises are positive, but the stock's future performance is heavily reliant on successful clinical development, regulatory approvals, and market adoption, which are inherently high-risk. The upcoming FDA meeting is a critical near-term catalyst. Given the progress but also the inherent risks of a biotech company, a 'hold' recommendation is appropriate for investors who are already positioned, awaiting further clarity on the regulatory path and continued clinical success.

Keywords

Revelation Biosciences, REVB, Financial Results, Q3 2025, Clinical-stage, Life Sciences, Gemini, Inflammation, Acute Kidney Injury, AKI, Chronic Kidney Disease, CKD, PRIME Clinical Study, Warrant Inducement, Cash Runway, Biotechnology, Drug Development, NASDAQ